Just Released: "Commercial Insight: Disease Modification in Rheumatoid Arthritis"

March 18, 2011 - PRLog -- In 2009, TNF inhibitors were the dominant drug class in terms of sales. However, there is growing use of non-TNF biologics at earlier lines of treatment, and this trend will continue over the next decade. With the first Phase III data from tasocitinib (CP-690,550; Pfizer) reaffirming efficacy with no new safety signals, novel oral small molecules could revolutionize the treatment of RA.
Features and benefits

* Gain insight into the RA market potential utilizing robust 10-year IMS- and patient-based forecasts, enabling commercial opportunity assessment
* Assess the future competitive landscape, with in-depth profiles of the leading marketed biologics
* Evaluate future patient numbers and brand dynamics by line of therapy
* Enhance understanding of future product potential, with key opinion leader views of late stage agents in the pipeline, such as tasocitinib and FosD

Highlights

New product launches, brand reformulations and further biologic uptake will grow the RA market to over $13bn in 2019. Using a patient-based approach, Datamonitor speculates that the RA market for biologics will double from 2009 to reach over 1million patients in 2019, translating to a value that could surpass $15bn.Datamonitor anticipates non-TNF biologics will be used more frequently at earlier lines of therapy. Bristol-Myers Squibb and Roche, which market Orencia (abatacept) and Actemra (tocilizumab), respectively, are attempting to change the game, with subcutaneous formulations and head-to-head studies against Humira (adalimumab; Abbott, Eisai).Tasocitinib (CP-690,550; Pfizer) demonstrated efficacy with no new safety signals in its first set of Phase III data. Despite ongoing debate over annual cost and positioning, rheumatologists believe tasocitinib has the potential to be a paradigm changing drug, and will achieve blockbuster status in the forecast period, reaching $1.3bn by 2019.
Your key questions answered

* What is the anticipated uptake of Cimzia (certolizumab) and Simponi (golimumab) and can these displace sales of the entrenched TNF brands?
* How will first-, second-, third- and fourth-line and above biologic brand dynamics change in the RA market across the 10-year forecast period?
* What is the potential market impact from Pfizer's tasocitinib, how will it be priced and how will rheumatologists position the novel small molecule?
* What impact will subcutaneous Orencia and Actemra have, and will these formulations help to propel non-TNFs further up the treatment algorithm?
* Who were the top company players in the rheumatoid arthritis market in 2009 and how will the landscape change to 2019?


For more information or to purchase this report, go to:
-  http://www.fastmr.com/prod/109694_commercial_insight_dise...


Partial Table of Contents:

Executive Summary
Strategic scoping and focus
Datamonitor insight into the rheumatoid arthritis market
Related reports
VERVIEW
Catalyst
Summary
MARKET DEFINITION
Market definition for this report
A7E0 - intestinal anti-inflammatory drugs
L1B0 - antimetabolites
L1X3 - antineoplastic MAbs
L4A0 - immunosuppressive agents
M1C0 - specific antirheumatic agents
ICD-10 codes used to define the rheumatoid arthritis market
MARKET OVERVIEW
Seven major markets
Current and future market overview
pportunities and threats
US
Current and future market assessment
pportunities and threats
Japan
Current and future market assessment
pportunities and threats
Five major European markets
Current and future market assessment
pportunities and threats
France
Current and future market assessment
Germany
Current and future market assessment
Italy
Current and future market assessment
Spain
Current and future market assessment
UK
Current and future market assessment
Rest of the world snapshot
Current market assessment
Brand Dynamics
verview of competitive landscape
Leading marketed products for rheumatoid arthritis
2010 pipeline update
Pipeline overview
Summary of discontinued products
B-cell therapies dropped from late-stage clinical developmentRituxan/MabThera (rituximab) remains the only B-cell targeted therapy available for the treatment of rheumatoid arthritis. With two notable pipeline candidates dropped from late-stage clinical development during the course of 2010, coupled with the increased competition among biologics players and future market landscape and new entrants, Datamonitor questions the clinical and commercial need for additional B-cell/CD20 targeted therapies. GlaxoSmithKline and Genmab recently announced that they were to cease development of the intravenous formulation of Arzerra (ofatumumab) in rheumatoid arthritis, but would instead focus on a subcutaneous (SC) formulation for multiple sclerosis and autoimmune indications. However, the companies have not yet formally announced their intentions to proceed with SC Arzerra in rheumatoid arthritis, with development in this indication under review.
crelizumab (Genentech/Roche, Biogen Idec)Genentech, with its partners Biogen Idec, Roche, and Chugai, was developing ocrelizumab, a second-generation fully human anti-CD20 monoclonal antibody for the potential treatment of rheumatoid arthritis. However, the companies announced in May 2010 that they would cease development of the drug in rheumatoid arthritis (
TRU-015 (Pfizer, Trubion)
Patient acquisition process
Introduction
Patient care path
Drivers of brand choice
Disease modification remains the most important driver of brand choice
US formulary tier status for leading brandsTier status in 2010
Trends in marketing strategies
Marketing strategy for leading brands
Marketing messages from ACR 2010Datamonitor attended the American College of Rheumatology (ACR) Scientific Meeting 2010, in Atlanta.
Tumor necrosis factor inhibitors
Enbrel (etanercept; Amgen/Pfizer/Takeda)
Remicade (infliximab; Centocor Ortho Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe)Drug profile
Humira (adalimumab; Abbott/Eisai)Drug profile

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=1096...

About Datamonitor

The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment.  

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.